---
title: "Hangzhou Tianmushan Pharmaceutical Enterprise Co.,Ltd (600671.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600671.SH.md"
symbol: "600671.SH"
name: "Hangzhou Tianmushan Pharmaceutical Enterprise Co.,Ltd"
industry: "Pharmaceuticals"
datetime: "2026-05-20T09:39:09.329Z"
locales:
  - [en](https://longbridge.com/en/quote/600671.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600671.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600671.SH.md)
---

# Hangzhou Tianmushan Pharmaceutical Enterprise Co.,Ltd (600671.SH)

## Company Overview

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces tablets, granules, pills, oral solutions, and other medications; and health food products, including oral liquids, syrups, eye drops, pills, soft capsules, tablets, and granules. It also sells prepared slices of traditional Chinese medicine. In addition, the company operates Chinese medicine clinic; provision of traditional chinese medicine clinic, software development, remote health management, commercial complex management, and internet information services; food business; and sale of health food products.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.hztmyy.com](https://www.hztmyy.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: D (0.60)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 211 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -15.71% |  |
| Net Profit YoY | -45.63% |  |
| P/B Ratio | 31.84 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2354513029.84 |  |
| Revenue | 204211455.11 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 24.90% | A |
| Profit Margin | 8.02% | B |
| Gross Margin | 54.76% | B |
| Revenue YoY | -15.71% | E |
| Net Profit YoY | -45.63% | D |
| Total Assets YoY | 8.06% | B |
| Net Assets YoY | 10.37% | B |
| Cash Flow Margin | 12.32% | D |
| OCF YoY | -15.71% | E |
| Turnover | 0.46 | C |
| Gearing Ratio | 79.12% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hangzhou Tianmushan Pharmaceutical Enterprise Co.,Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-15.71%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-45.63%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "31.84",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2354513029.84",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "204211455.11",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "24.90%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "8.02%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "54.76%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-15.71%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-45.63%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.06%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "10.37%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "12.32%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-15.71%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.46",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "79.12%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 143.80 | 153/215 | 76.78 | 63.59 | 53.35 |
| PB | 31.84 | 219/215 | 37.18 | 33.89 | 30.43 |
| PS (TTM) | 11.53 | 192/215 | 10.09 | 8.62 | 7.35 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600671.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600671.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600671.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600671.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**